Gotu Kola for Venous Insufficiency and Circulation
Heavy, aching legs that swell by evening. Ankles that leave a sock mark. A dull throb after a day standing at work, relieved by putting your feet up. That cluster is chronic venous insufficiency, and it is the second of gotu kola’s two evidence-backed uses — the one where the standardised extract was studied hardest, by a small number of European research groups, mostly between 1987 and 2001.
That date range is the whole story of this article. The evidence is real, it is measured with objective instruments rather than opinion, and it is old, small, concentrated in a handful of laboratories, and published substantially in a single sponsored journal supplement. All of that is knowable from the papers themselves, and all of it is left out of supplement copy. Here it is in full.
Table of Contents
- What Chronic Venous Insufficiency Actually Is
- Why a Connective-Tissue Herb Was Tried Here
- TTFCA and the Doses Actually Studied
- The 1987 Multicentre Trial
- The Italian Microcirculation Programme
- What the 2013 Systematic Review Concluded
- Flight Oedema and Diabetic Microangiopathy
- The Honest Limitations
- Where It Fits Beside Compression
- Practical Use
- Cautions and Red Flags
- Key Research Papers
- Connections
- Featured Videos
What Chronic Venous Insufficiency Actually Is
Leg veins have to move blood uphill. They manage it because the calf muscles squeeze them with every step and one-way valves stop the blood falling back between squeezes. When those valves leak — from age, pregnancy, genetics, prolonged standing, obesity or a previous clot — blood pools in the lower leg and the pressure inside the veins stays high even when you are walking. That sustained pressure is called venous hypertension, and it is what does the damage.
High pressure pushes fluid out of the capillaries into the tissue faster than the lymphatics can clear it. That is the swelling. Over years the leaked fluid carries proteins and red cells with it, and the skin around the ankle becomes discoloured, thickened and fragile — and eventually, in some people, ulcerates.
The clinical stages run roughly: telangiectasia and spider veins, then varicose veins, then oedema, then skin changes (pigmentation, eczema, lipodermatosclerosis), then healed ulcer, then active ulcer. Gotu kola has been studied at the early and middle end of that ladder — symptoms, oedema and capillary leak. It has not been shown in a randomised trial to heal ulcers or to prevent progression to them. One 2025 registry from the same Chieti research group, which was not randomised or blinded, reported faster ulcer closure when an oral standardised Centella extract was added to standard ulcer care (details under The Honest Limitations).
Why a Connective-Tissue Herb Was Tried Here
The rationale is the same chemistry that underlies the wound-healing use, pointed at a different tissue. A vein wall is largely connective tissue — collagen, elastin and the cells that maintain them. A capillary wall is a single layer of endothelium sitting on a basement membrane. If a compound modulates fibroblast behaviour, collagen synthesis and endothelial integrity, then a leaky, distensible, chronically stretched vein is a reasonable place to test it.
The specific claims made for the triterpenic fraction in this setting are that it improves the tone and reduces the distensibility of the vein wall, and that it reduces the abnormal permeability of the capillaries in the affected skin. Both were tested with instruments rather than questionnaires, which is the strongest single feature of this literature.
TTFCA and the Doses Actually Studied
The venous trials used the standardised fraction, referred to as TTFCA (total triterpenic fraction of Centella asiatica) or TECA (titrated extract). It is not dried leaf and not a tea.
| Study | Regimen | Daily total | Duration |
|---|---|---|---|
| Pointel 1987 | Two arms versus placebo | 60 mg and 120 mg | 2 months |
| Belcaro 1990 | 60 mg three times daily | 180 mg | 2 weeks |
| Cesarone 1994 | 30 mg or 60 mg twice daily versus placebo | 60 mg and 120 mg | 60 days |
| De Sanctis 2001 | 30 mg or 60 mg three times daily | 90 mg and 180 mg | 4 weeks |
| Incandela 2001 (venous) | Two dose levels versus placebo | 60 mg and 120 mg | Short term |
| Cesarone 2001 (flights) | 60 mg three times daily | 180 mg | 2 days before, day of, 1 day after flight |
| Incandela 2001 (diabetic) | 60 mg twice daily | 120 mg | 12 months |
| Cesarone 2001 (diabetic) | 60 mg twice daily | 120 mg | 6 months |
So the studied range is roughly 60 to 180 mg of the triterpenic fraction per day, in two or three divided doses, for periods from a few days to a year. Where dose-ranging was done, higher doses generally did more: De Sanctis and colleagues concluded that 180 mg/day beat 90 mg/day, and Incandela and colleagues distinguished 120 mg/day from 60 mg/day on objective measures.
The 1987 Multicentre Trial
The most conventionally designed study in the set is also the oldest. Pointel and colleagues, publishing in Angiology in 1987, enrolled 94 patients with venous insufficiency of the lower limbs into a multicentre, double-blind, placebo-controlled trial. After randomisation they received TECA 120 mg/day, TECA 60 mg/day, or placebo for two months.
Findings:
- Significant benefit (p < 0.05) for TECA over placebo on heaviness in the legs and oedema, and on the patient’s own overall assessment.
- Venous distensibility, measured with a mercury strain-gauge plethysmograph at three occlusion pressures, improved in both TECA groups — and worsened in the placebo group over the same two months.
That last detail is worth pausing on. The instrument result was not merely “treated group better” but “treated group improved while untreated group deteriorated”, over a period long enough for natural progression to show. It is the single most persuasive piece of data in the gotu kola venous literature. It is also thirty-nine years old, with roughly thirty patients per arm, reported in an abstract that does not describe the randomisation or blinding procedure in any detail.
The Italian Microcirculation Programme
Nearly everything else comes from one interconnected research effort centred on Gianni Belcaro, Maria Rosaria Cesarone, Maria Teresa De Sanctis and Luciano Incandela, working between the G. D’Annunzio University in Chieti, Italy and the Irvine Vascular Laboratory at St Mary’s Hospital, London. Their contribution was methodological: instead of asking patients whether their legs felt better, they built a battery of microcirculatory measurements.
The instruments, in plain terms
- Capillary filtration rate (CFR) — how fast fluid leaks out of the capillaries into the tissue, measured by venous occlusion plethysmography. Higher means leakier.
- Rate of ankle swelling (RAS) — how quickly the ankle enlarges over a standardised period. A direct proxy for oedema formation.
- Laser Doppler flowmetry — skin blood flux at rest, plus the venoarteriolar response, a reflex that should shut down skin flow when you stand. In venous disease that reflex is blunted.
- Transcutaneous PO2 and PCO2 — oxygen and carbon dioxide measured through the skin. Poor microcirculation shows as falling oxygen and rising carbon dioxide.
- Vacuum suction chamber (VSC) — raises a small wheal on the skin near the ankle and times how long it takes to disappear. Longer means more capillary leak.
What they reported
Belcaro 1990 used the VSC device with laser Doppler in 10 normal subjects, 22 patients with moderate superficial venous hypertension and 12 with post-phlebitic limbs and severe venous hypertension. Each was observed for two weeks untreated, then treated for two weeks with TTFCA 60 mg three times daily. Wheal disappearance time was longer in the patients than the controls at baseline, unchanged over the untreated fortnight, and significantly shorter after treatment — alongside improvement in microcirculatory measures and symptoms. The untreated run-in period is a genuine strength: it shows the change tracked the drug rather than the passage of time.
De Sanctis 2001 was a dose-ranging, placebo-controlled study: 20 patients on 180 mg/day, 20 on 90 mg/day, 12 on placebo, and 10 healthy subjects also given 180 mg/day as a reference. After four weeks, capillary filtration rate, ankle circumference and ankle-swelling time all fell significantly in the treated patients, more so at the higher dose. Nothing changed on placebo — and, notably, nothing changed in the healthy subjects taking the drug, which is what you would expect if the effect depends on abnormal capillary leak being present in the first place.
Incandela 2001, a single-blind, placebo-controlled, randomised study, combined laser Doppler with transcutaneous gas measurements in patients with venous hypertensive microangiopathy, and found that the whole battery separated 120 mg/day from 60 mg/day from placebo, with symptom scores moving in parallel with the instrument readings.
Cesarone 1994, published in Italian in Minerva Cardioangiologica, was an earlier double-blind study of microcirculatory activity in venous insufficiency from the same group. It enrolled 87 patients with venous hypertensive microangiopathy, who took 30 mg twice daily, 60 mg twice daily, or placebo for 60 days. Compared with the values at the start, the abnormally raised resting skin flux improved, transcutaneous PCO2 fell and PO2 rose; the effects appeared dose-related, and no unwanted effects were observed.
What the 2013 Systematic Review Concluded
Chong and Aziz at the University of Malaya searched thirteen electronic databases including the Cochrane Central Register for randomised trials of Centella asiatica in chronic venous insufficiency. Eight studies met inclusion criteria, and two authors independently extracted data.
Their findings:
- Pooling comparable studies showed significant improvement in microcirculatory parameters — transcutaneous PCO2 and PO2, rate of ankle swelling, and venoarteriolar response.
- Three of the eight studies reported no quantitative data at all, describing improvement in leg heaviness, pain and oedema without numbers to pool.
- Their stated conclusion: Centella asiatica may be beneficial for signs and symptoms of chronic venous insufficiency, but this “needs to be interpreted with caution as most of the studies were characterised by inadequate reporting and thus had unclear risks of bias, which may threaten the validity of the conclusions”.
That is a fair verdict and worth reading twice. The direction of effect is consistent. The quality of the underlying reports is not good enough to be confident about the size of it.
A 2026 network meta-analysis
A 2026 network meta-analysis compared drug treatments for chronic venous disease across 51 randomised trials with 6,800 patients. Centella asiatica significantly reduced leg heaviness compared with control (risk ratio 0.30, 95% confidence interval 0.11 to 0.81), as did calcium dobesilate. The treatments that significantly improved ulcer healing in that analysis were pentoxifylline, micronised purified flavonoid fraction and sulodexide.
Flight Oedema and Diabetic Microangiopathy
The same group extended TTFCA into two adjacent problems.
Flight-related leg swelling. Cesarone and colleagues studied passengers aged 30–50 with mild-to-moderate superficial venous disease and varicose veins, travelling in economy class on flights longer than three hours. The treated group took TTFCA 60 mg three times daily for two days before the flight, on the day itself, and for one day after. In untreated controls, carbon dioxide, rate of ankle swelling and oedema score rose progressively with flight time while skin flux and the venoarteriolar response fell. In the TTFCA group the changes in all measures were milder, though that difference was not statistically significant (p > 0.05), and ankle swelling and oedema were significantly lower (p < 0.025). Note that the control group received no treatment at all — there was no placebo, so expectation effects are uncontrolled.
Diabetic microangiopathy. Incandela and colleagues ran a twelve-month placebo-controlled study of TTFCA 60 mg twice daily in patients with diabetic microangiopathy, with and without neuropathy, alongside healthy controls. Resting flux and rate of ankle swelling fell in the treated groups, with a corresponding decrease in oedema; untreated patients deteriorated progressively over the year while healthy subjects did not change. A companion paper from the same programme (Cesarone 2001) studied 50 people with diabetic microangiopathy: 30 took TTFCA 60 mg twice daily for six months, 10 took placebo and 10 received no treatment. After six months neither control group had changed significantly, while in the treated group resting skin flux fell, the venoarteriolar response improved, PO2 rose, PCO2 fell and the abnormally raised capillary leak (rate of ankle swelling) decreased. Twelve months is a long study for a botanical, and progressive deterioration in the placebo arm is a meaningful comparator.
The same laboratory also published a study on the echogenicity of carotid plaques after TTFCA in the same 2001 supplement, which gives a sense of how broadly the group was testing this single compound.
The Honest Limitations
Five, in order of importance.
- One research programme dominates the evidence. A large share of the trials share overlapping authors, a shared laboratory, and shared methods. Independent replication by unconnected groups is what converts a promising finding into an established one, and it has largely not happened here. The newest addition comes from the same Chieti laboratory: a 2025 registry of 160 people with venous ulcers, 80 of whom took an oral standardised Centella extract (675 mg a day for three months) on top of standard ulcer care while 80 received standard care alone. Average ulcer area fell from 2.34 to 0.33 cm² with the extract and from 2.4 to 1.61 cm² without it, and 96.2% versus 83.7% of ulcers closed completely. The study was not randomised or blinded, so it extends the single-group problem rather than resolving it.
- Much of it appeared in a single journal supplement. Angiology volume 52, supplement 2, October 2001, carries a run of TTFCA papers back to back. Supplement issues are frequently sponsored and are not always subject to the same peer review as the parent journal. This does not make the data false. It does mean they carry less weight than the same results in a regular issue.
- The endpoints are mostly surrogates. Capillary filtration rate and transcutaneous gas tensions are legitimate physiological measures, and better than a satisfaction score — but no trial shows that treating them with gotu kola prevents a venous ulcer, prevents progression, or reduces the need for a procedure. Those are the outcomes patients actually care about.
- The studies are small and short. Arms of 10 to 30 patients. Durations of two to eight weeks, with a six-month and a twelve-month exception. Nothing here is a modern multicentre trial.
- Reporting quality is poor by current standards. The systematic reviewers said so directly, and three of eight trials could not even be pooled for want of numbers.
Where It Fits Beside Compression
Compression is the foundation of venous care, and nothing displaces it. Graduated compression stockings work by external mechanics: they oppose the pressure driving fluid out of the capillaries. Calf-muscle activity, leg elevation, and weight management do the same job from other directions. For varicose veins with symptoms, endovenous ablation and related procedures treat the underlying reflux.
Venoactive drugs — the class gotu kola belongs to — are adjuncts to that, not substitutes. The class also includes micronised purified flavonoid fraction (diosmin and hesperidin), horse chestnut seed extract, ruscus preparations and hydroxyethylrutosides. Some of those have a larger trial base than gotu kola does.
A 2020 Cochrane review looked at these drugs as a class (called phlebotonics). It included 69 randomised trials, 56 of which gave usable data on 7,690 people; two of those tested Centella asiatica. Compared with placebo, it found that the class probably reduces lower-leg swelling slightly (risk ratio 0.70, moderate certainty) and probably makes little or no difference to quality of life (moderate certainty), and that the drugs may have little or no effect on ulcer healing (risk ratio 0.94, low certainty). They probably cause slightly more side effects than placebo (risk ratio 1.14, moderate certainty), most often stomach and bowel upset. The trials gave only short-term safety data.
| Measure | Realistic expectation from TTFCA |
|---|---|
| Leg heaviness and aching | Modest improvement, seen in trials |
| Ankle and leg swelling | Measurable reduction at 90–180 mg/day |
| Capillary leak measures | Consistently improved in instrumented studies |
| Visible varicose veins | No evidence of change |
| Preventing ulcers or progression | Not demonstrated |
| Replacing compression | No — nothing supports this |
Practical Use
- The product the trials used. Every venous trial used a standardised triterpenic fraction (TTFCA, or TECA, the “titrated extract”). Unstandardised dried-leaf capsules were not what any of these trials used, and their triterpene content is unknown.
- The doses studied. The trials used 60–180 mg/day of the triterpenic fraction, split into two or three doses. Most trials sat at 120–180 mg/day.
- The time course. Most of the venous trials ran four to eight weeks. The instrumented changes appeared over two to four weeks; symptom change generally lags.
- Length of use. The liver case reports involved 30, 20 and 60 days of continuous oral use. Traditionally the herb has been taken in time-limited courses with breaks.
- Compression and the everyday measures. A 2026 review describes compression as the cornerstone of conservative care for chronic venous disease and weight management as a foundational strategy; walking and elevating the legs above heart level for periods each day are the other everyday measures.
- Long flights. The studied regimen started two days before travel. Hydration, an aisle seat, calf exercises and compression socks are the other measures commonly used against flight swelling.
Cautions and Red Flags
- One-sided leg swelling, especially with calf pain, warmth or redness, or with breathlessness or chest pain, is a sign of possible deep vein thrombosis or pulmonary embolism, which hospitals treat as an emergency — not a herb problem.
- A leg ulcer needs proper wound care and vascular assessment. No botanical substitutes for compression bandaging and an ankle-brachial pressure index.
- New or rapidly worsening swelling in both legs can reflect heart, kidney or liver disease, or a drug side effect (calcium channel blockers are a common culprit). Those are separate conditions with their own treatments, and gotu kola does not treat them.
- Liver. Rare hepatotoxicity has been reported with oral Centella asiatica — see the forms and safety article. In a 2005 case series, three women aged 61, 52 and 49 developed jaundice after taking Centella asiatica for 30, 20 and 60 days, with the liver enzyme ALT reaching 1,193, 1,694 and 324 U/L. Liver biopsy showed granulomatous hepatitis in two and chronic hepatitis with cirrhotic change in one. All three improved after stopping the herb (they were also given ursodeoxycholic acid), and the first woman’s liver injury came back when she took it again. The research raises a concern for people who already have liver disease. Unexplained fatigue, nausea, dark urine and jaundice are signs of liver injury that hospitals treat as urgent.
- Pregnancy and breastfeeding. There is no safety data for oral use in pregnancy or breastfeeding. Pregnancy-related leg swelling is common, and none of the trials on this page studied it.
- Sedation and surgery. Possible additive effect with alcohol, sedatives and anaesthesia. Surgical teams commonly ask for herbal supplements to be stopped about two weeks before planned surgery.
- Diabetes medication. The six- and twelve-month diabetic trials measured microcirculation and swelling, not blood sugar, and no trial on this page shows that gotu kola lowers glucose. It was studied for the small-vessel damage of diabetes, not as a treatment for diabetes itself.
Key Research Papers
- Chong NJ, Aziz Z. A systematic review of the efficacy of Centella asiatica for improvement of the signs and symptoms of chronic venous insufficiency. Evidence-Based Complementary and Alternative Medicine. 2013;2013:627182 — PubMed PMID: 23533507 — Eight trials; benefit on microcirculatory parameters; unclear risk of bias throughout.
- Pointel JP, Boccalon H, Cloarec M, Ledevehat C, Joubert M. Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology. 1987;38(1 Pt 1):46–50 — PubMed PMID: 3544968 — 94 patients, multicentre, double-blind, 60 and 120 mg/day versus placebo.
- Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology. 1990;41(7):533–540 — PubMed PMID: 2389834 — Vacuum suction chamber study with a two-week untreated run-in.
- De Sanctis MT, Belcaro G, Incandela L, Cesarone MR, Griffin M, Ippolito E, et al. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Angiology. 2001;52(Suppl 2):S55–S59 — PubMed PMID: 11666125 — 180 mg/day outperformed 90 mg/day.
- Incandela L, Belcaro G, De Sanctis MT, Cesarone MR, Griffin M, Ippolito E, et al. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology. 2001;52(Suppl 2):S61–S67. — PubMed PMID: 11666126
- Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C, et al. [The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study.] Minerva Cardioangiologica. 1994;42(6):299–304 — PubMed PMID: 7936334 — In Italian.
- Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, et al. Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001;52(Suppl 2):S33–S37 — PubMed PMID: 11666121 — No placebo arm — controls were untreated.
- Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Nargi E, Patricelli P, et al. Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled randomized study. Angiology. 2001;52(Suppl 2):S27–S31 — PubMed PMID: 11666119 — Twelve months, 120 mg/day.
- Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M, et al. Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiatica: a clinical prospective randomized trial with a microcirculatory model. Angiology. 2001;52(Suppl 2):S49–S54. — PubMed PMID: 11666124
- Cesarone MR, Belcaro G, Nicolaides AN, Geroulakos G, Bucci M, Dugall M, et al. Increase in echogenicity of echolucent carotid plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled, randomized trial. Angiology. 2001;52(Suppl 2):S19–S25 — PubMed PMID: 11666118 — Included to show the breadth of the same programme, not as evidence of cardiovascular benefit.
- Grimaldi R, De Ponti F, D’Angelo L, Caravaggi M, Guidi G, Lecchini S, et al. Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid. Journal of Ethnopharmacology. 1990;28(2):235–241 — PubMed PMID: 2329813 — Confirms oral absorption.
- Nguyen AN, Ta KT, Chuang KJ. Pharmacological interventions to treat chronic venous disease: a network meta-analysis. Phlebology. 2026 (online ahead of print). — PubMed PMID: 42529868 — 51 trials, 6,800 patients; Centella reduced leg heaviness.
- Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. 2020;11(11):CD003229. — PubMed PMID: 33141449 — The drug class as a whole; two Centella trials included.
- Belcaro G, Dugall M, Cesarone MR, Ledda A, Ippolito E, Corsi M, Hosoi M, Scipione V, Scipione C, Cotellese R, Feragalli B. Improvement in venous ulcer closure and healing with Centellicum®. Minerva Surgery. 2025;80(4):308–313. — PubMed PMID: 40719428 — Non-randomised registry, 160 people with venous ulcers.
- Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Revista Española de Enfermedades Digestivas. 2005;97(2):115–124. — PubMed PMID: 15801887 — Three cases of liver injury.
- Fogacci F, Di Micoli V, Avagimyan AA, ALGhasab NS, Perone F, Cicero AFG. Lifestyle strategies and nutraceuticals in chronic venous disease: an evidence-weighted synthesis and clinical positioning. Clinical Nutrition. 2026;66:106801. — PubMed PMID: 42828782
- Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine. 2000;7(5):427–448 — PubMed PMID: 11081995 — Reviews the venous literature as it stood in 2000.
PubMed Topic Searches
- PubMed: Centella asiatica and chronic venous insufficiency
- PubMed: TTFCA and capillary filtration
- PubMed: Venoactive drugs in chronic venous disease — guidelines
- PubMed: Horse chestnut seed extract — the better-studied comparator
- PubMed: Compression therapy for venous leg ulcers
- PubMed: Centella asiatica and diabetic microangiopathy